A significant advantage of rubitecan is that the drug can be given orally on an outpatient basis, thus providing convenience for patients. This is in contrast to other cancer drugs that have to be given intravenously either in a hospital or physician's office. Rubitecan has also shown activity in hematologic tumors as well.
Several advantages distinguish rubitecan as a potential therapy for treating cancer.
One advantage is its side-effect profile relative to other anticancer drugs. The company that makes PC Spes to treat prostate cancer also makes a herbal preparation to treat breast and certain other cancers called Spes . The Spes preparation has been shown effective in the 2 years that Foundation members have been using it. What follows is a highly technical description of the molecular mechanisms of action of Spes . Please don't be intimidated if you can't understand all of this as it is written to inform the oncologist as well as the lay reader.